Method Validation · Analytical Methods

Does your method prove what the result claims — reviewed, or built?

Two ways in. Have a validation package? Get an independent read on whether the data really proves the method is specific, accurate, and stability-indicating, at the depth you choose. Need one? Send your method and product and we build the validation from scratch.

The trendA top-cited lab finding

Scientifically sound laboratory controls (21 CFR 211.160(b)) are a recurring drug GMP Form 483 finding — the requirement that test procedures and the specifications behind them be scientifically sound and proven for their purpose, not merely written and on file.

FDA drug GMP inspectional-observation data · 21 CFR 211.160(b)

What this is

Whether the method measures what it has to — against the rules, and against your own data.

Method validation is the proof that an analytical method is specific, accurate, precise, and able to detect the failure it exists to catch — on the product and the matrix you actually test. We judge the validation you hold, or build the one you’re missing, against ICH Q2 and USP <1225> and against what your own executed data shows, not just whether the protocol reads correctly.

Method Validation Opinion Letter

An independent regulatory opinion on the validation you already have — does it hold up. Start at the base; add the records that take the read past the paper.

What this covers

Analytical method validation — ICH Q2 / USP
Method suitability & transfer
Method defensibility — stands up to an out-of-spec investigation

What you get back

A signed written opinion you can file in your quality system, or use to catch a gap before an inspection or an out-of-spec investigation instead of after. Each part read against the rule and against your records, with a clear conclusion and what it would take to address it. It’s an independent recalculation from your own data. Not the lab that ran the validation grading its own work, and not a remediation job that reviews as step one — we have no lab to feed. It catches the method that reads validated on paper and fails when someone recalculates from the raw data.

What a review catches

A worked validation — a method that passes at release and can’t see the shelf-life failure.

A constructed example: a finished-product method with a complete validation report, every result Pass, the dossier marked validated. Here is what the deeper read surfaced once the executed data and the acceptance basis were actually opened — each catch tied to the real rule.

Specimen drawn from the GMP Guard™ case — a method carried from the caplet that can’t see the degradant

01The method was carried from the caplet — and never revalidated for the softgel.

Reads asA validated dissolution method, results Pass, on the new softgel SKU.

Hiding in itCarried from the caplet, never revalidated for the softgel — never shown to be discriminating or stability-indicating.

Why it mattersA method validated on one dosage form isn’t validated on another — blind to the softgel’s shelf failure, gelatin cross-linking.

USP <711> / ICH Q2 · method revalidation

02It isn’t stability-indicating — it can’t see the degradant.

Reads asA finished-product assay, acceptance criteria met at release.

Hiding in itNo stability-indicating impurity method — the toxic degradant, 4-aminophenol, never resolved or measured.

Why it mattersA method that can’t quantify the degradant passes a degraded lot — clean because it’s blind.

21 CFR 211.166(a)(3) · stability-indicating method

03The reference standard for the impurity was never procured.

Reads asA specification that names the impurity limit.

Hiding in itThe degradant reference standard never on hand — the impurity unquantifiable at any gate.

Why it mattersNo standard, no way to validate accuracy or specificity — the impurity result is unanchored.

USP <11> · reference standards

!The release spec drops the impurity test entirely.

Reads asA finished-product spec, the assay validated and in place.

Hiding in itRelease spec omits the monograph 4-aminophenol limit test — carried forward from a supplier COA, never re-measured.

Why it mattersA validated assay you never run for the degradant proves nothing about the degradant.

USP Acetaminophen monograph / 21 CFR 211.165

Build your review

Standardthe baseline the field expects

Included

The validation, on its face$2,500

Judges the validation protocol and report against ICH Q2 and USP <1225> as written — scope, the validation characteristics claimed, acceptance criteria, and conclusions — whether it reads correctly and is complete and defensible on its face.

You send: Analytical Method Validation ReportYour analytical method validation protocol and report — the validation characteristics claimed, the acceptance criteria, and the conclusions.Also called: method validation report, AMV report, validation protocolFull details on the Records page

Exceeding Standardstested against your own data

Optional add-on — tap to add

The validation data supports the claims+ $3,000

A summary that says the method is accurate is not the same as data that prove it. Send the raw data package and we recalculate — accuracy, precision including intermediate precision, specificity, linearity, and range — to see whether the numbers in the report actually come back from the source data, or were only asserted in the summary.

You also send: Method Validation Raw Data PackageThe raw data behind the validation report — used to recalculate accuracy, precision, specificity, linearity, and range from the source, not the summary.Also called: validation raw data, source data package, executed validation dataFull details on the Records page

Optional add-on — tap to add

The method is verified in your conditions of use+ $1,900

A method validated in one lab on one matrix is not proven in yours. Add your transfer or matrix-verification records and we check whether the method was actually verified for your specific product matrix or transferred to the receiving lab, with the acceptance criteria met — so the method works where you actually run it, not just where it was developed.

You also send: Method Transfer / Verification ReportYour method-transfer or matrix-verification records — showing the method was verified for your product matrix (USP <1226>) or transferred to the receiving lab (USP <1224>).Also called: method transfer report, method verification, matrix verificationFull details on the Records page

If your validation can’t be given a clean opinion on what you send, you get a straight report on what’s missing instead, at the same fee.

Your review$2,500base only

Method Validation Protocol Development

No defensible validation yet? Send your method and product and we build the validation package from scratch — one flat fee, built to the standard an auditor applies, independent of any instrument or lab vendor.

What this covers

Analytical method validation — ICH Q2 / USP
Method suitability & transfer
Method defensibility — stands up to an out-of-spec investigation

What you get back

You get the built validation package, ready to execute and file. It states what the method has to prove and lays out a risk-based protocol: the right ICH Q2 characteristics, forced-degradation and stability-indicating design, and acceptance criteria tied to your product’s real degradation pathway. Method-transfer and revalidation logic are built in. It is grounded in what the method actually has to catch, not a generic template for a different molecule. And where the method can’t be made stability-indicating as it stands, you get the path to fix it at the same price — never a validation that sets the bar where the method already passes.

What you send

The specifics we build from: the method and what it has to measure; your product matrix and its degradation pathway — the form you make and the impurities that matter; and the standard or specification the method has to support, plus any existing method or development data you already have.

What this builds

The same method, with no defensible validation — the calls we made, and why.

Nothing to catch on a build: you send the method and the product, and the reasoning is the work. Here is the same constructed finished-product method — an analgesic softgel with a toxic degradation product — brought to us to validate from scratch, and the call we made at each step.

You send the method, the product, and any development data — the starting context lives on the GMP Guard™ case

01We make the method stability-indicating against the real degradant.

We design forced degradation and a peak-purity check to resolve and quantify the toxic degradant — so the method is built to see the failure, not just the fresh, clean sample.

ICH Q2 / Q3B · stability-indicating

02We revalidate for the actual dosage form, not inherit it.

We design revalidation for the softgel — discriminating, two-tier dissolution on aged samples — instead of reusing the caplet method, so the method matches the form it actually runs on.

USP <711> · discriminating method

03We anchor it to traceable standards and design the transfer.

We build in the requirement to source and qualify the degradant reference standard, anchor accuracy and specificity to it, and define method-transfer and revalidation triggers — so a result means something at every lab and after every change.

USP <11> / <1224>

!And the honest fork, up front: if the method can’t be made stability-indicating, we say so.

Where the existing method can’t be made to resolve the degradant without a different technique, we said so and gave the path — redevelop the method — rather than a validation that sets the bar where the blind method already passes.

Method capability basis

Built validation package$5,000fixed price

Common questions

Straight answers.

My method came from a compendial monograph. Isn’t that enough?

A compendial method still has to be verified under your conditions, on your matrix and form — and a monograph assay isn’t automatically stability-indicating for your degradation pathway. Verification and the stability-indicating question are the gaps a monograph leaves, and we close them.

Isn’t a template pack cheaper?

Much. And it hands you blank validation forms and leaves the hard part — defining what the method has to catch, the forced-degradation design, the acceptance criteria — for you to derive and defend. You’re buying the judgment a blank form can’t give you.

Do you run the method or operate the lab?

No. The review judges your package; the build writes it. Neither runs the assay on your instruments or operates the lab — that keeps the opinion independent of anyone selling you the column or the hours. You execute it in-house or with whoever you choose.

What if the method can’t be validated as it stands?

You get told that plainly, at the same fee. We don’t write a validation that sets the bar where a blind method already passes. Sometimes the answer is to redevelop the method — we lay out the path and you decide.

Is this the same as process validation?

No — related but distinct. Method validation proves the test measures what it claims; process validation proves the process makes good product, run after run. This is the analytical layer; the process layer is its own review.

Is this legal advice?

No — it is an independent regulatory opinion or a built work product, not legal counsel, and it creates no attorney-client relationship. If your question is whether the validation holds up against the rule and your data, that is ours.

Where to go from here.

Regulatory work product, not legal advice. A deliverable is prepared from the records you submit and is not legal counsel, not a guarantee of any regulatory or customer outcome, and forms no attorney-client relationship. It is a document review or build — not a GMP audit, not method execution, instrument qualification, or lab testing, and not the disposition or release decision. Where the records provided can’t support a defensible result, we deliver a findings report on what’s missing instead. GMP Guard™ is a constructed teaching case; no real company or product is depicted.